<DOC>
	<DOCNO>NCT00216294</DOCNO>
	<brief_summary>The purpose study determine safety tolerability RG1068 ( Synthetic Human Secretin ) administer three time weekly outpatient obsessive compulsive disorder ( OCD ) , determine impact multiple subcutaneous injection RG1068 symptom OCD , measure change clinical scale , evaluate effect RG1068 ODC patient ' anxiety , quality life , depression .</brief_summary>
	<brief_title>Safety Study Drug RG1068 Patients With Obsessive Compulsive Disorder</brief_title>
	<detailed_description>This open-label , dose-escalation pilot study . Prospective participant initially undergo blind placebo challenge assess ability self-administer drug . A total sixteen subject , enrol one two study arm ( eight subject per group ) , depend whether receive concurrent treatment SSRI . The first 8 patient enrol receive subcutaneous injection RG1068 10 µg/kg divide receive SSRI ’ receive SSRI ’ . Those receive SSRI treatment divide newly diagnose , SSRI-naïve patient patient receive SSRI ’ past discontinue treatment least twelve week prior enrollment . If drug-related serious adverse event , additional eight patient enrol receive RG1068 20 µg/kg . This group also divide receive SSRI ’ receive SSRI ’ . Those receive SSRI treatment divide manner ; newly diagnose , SSRI-naïve patient , patient receive SSRI ’ past discontinue treatment least twelve week prior enrollment .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Compulsive Personality Disorder</mesh_term>
	<mesh_term>Obsessive-Compulsive Disorder</mesh_term>
	<mesh_term>Compulsive Behavior</mesh_term>
	<mesh_term>Secretin</mesh_term>
	<criteria>1. outpatient primary DSMIV diagnosis OCD 2. age 1840 year , inclusive 3. moderate severe symptom OCD : ) YBOCS score ≥24 ; b ) CGISeverity ≥4 ; c ) significant disruption daily activity ( ≥2 item 1 6 YBOCS ) ; ) disruption employment/education function ( ≥2 item 2 7 YBOCS ) 4. SSRI , must : ) discontinue treatment SSRI least 12 week prior study Day 1 ; b ) treatment naïve . 5. SSRI : ) must residual symptom despite three month trial adequate dose SSRI drug ; b ) must currently SSRI least 16 week stable regimen least 8 week prior Day 1 . 6 . Competent give inform consent . 1. moderate severe depression ( MADRS &gt; 25 ) 2. significant risk suicidal behavior screen 3. surgical lesion anterior capsule ( capsulotomy ) cingulate gyrus ( cingulotomy ) 4. comorbid tic , Tourette syndrome , schizoobsessive disorder , pure obsessive disorder Axis II disorder 5. first degree relative Tourette syndrome 6. pediatric autoimmune neuropsychiatric disorder associate streptococcal infection ( PANDAS ) 7. current cognitive behavioral psychotherapy 8. history sensitivity ingredient study drug 9 . Clinically significant abnormality screen laboratory result 10 . Clinically significant organic disease ( OCD ) , include cardiovascular , hepatic , pulmonary , neurologic , renal disease , medical condition , serious intercurrent illness , extenuate circumstance , opinion Investigator , would interfere performance interpretability , put patient risk , study procedure 11. current , active ongoing DSMIV Axis I psychiatric disorder anxiety disorder , major depression , dysthymia , depression otherwise specify ( include organic mental syndrome disorder dementia ) long secondary diagnosis . 12. woman pregnant , breastfeeding , refuse use adequate birth control 13. diagnosis alcohol substance abuse and/or dependence past 6 month 14. participate investigational drug study within 28 day Day 1 15. concomitantly use psychotropic medication SSRI chloral hydrate sleep 16. receiving treatment monoamine oxidase inhibitor within 2 week , depot neuroleptic within 6 month , neuroleptic , anxiolytic , antidepressant daily basis 2 week prior Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>Obsessive Compulsive Disorder</keyword>
	<keyword>RG 1068 ( Synthetic Human Secretin )</keyword>
</DOC>